黄芪注射液治疗肺心病急性加重期73例疗效观察

目的:探讨黄芪注射液静脉注射治疗肺心病急性加重期的疗效.方法:对照组67例,采用常规的抗感染、平喘、强心及利尿等治疗;治疗组73例,在常规治疗的基础上同时加用黄芪注射液40mL溶于5%葡萄糖250mL中静脉滴注,每日一次,10d为一疗程.结果:治疗组和对照组的有效率分别为91.78%和74.63%(P<0.01);两组治疗后心输出量(CO,L/minm2)、心脏指数(CI)、左室射血分数(LVEF)、左室短轴缩短率(FS)、每搏输出量(SV)、二尖瓣快速充血期和心房收缩期血流速度(E/A)均较治疗前明显改善(P<0.05,P<0.01),但治疗组更优于对照组(P<0.05).两组动脉血气治疗后均有改善,但治疗组改善程度优于对照组(P<0.05).结论:黄芪注射液对肺心病急性加重期具有较好疗效.

Study on Effect of Astragalus Injection in Treating Pulmonary Heart Disease on Severe Stage: with 73 Cases

Objective: To observe the clinical efficacy and side-effects of Astragalus injection(AI) in treating congestive heart failure(CHF) on severe stage.Methods: 140 patients of CHF with heart function on 2~4 grade assessed by NYHA(New York Heart As-sociation) were randomly divided into 2 groups.The 73 patients in the treated group were treated with AI 40mL(equivalent to 80g crude drug) by adding in 5% glucose solution 250 mL for intravenous driping,once a day and the 67 patients in the control group were treated by nitrolingual injection 15mg by adding in 5% glucose solution 500mL for intravenous in-jection driping,once a day,The therapeatic course in both groups were 10 days and the patients were followed-up for 1-6 months.Results: the clinical heart function improvement rate and the total effective rate in the treated group after 1 month treatment were 26.2% and 78.6%,and after 6 months were 34.2% and 81.6% respectively,which were superior to those in the control group significantly(P < 0.05 or P < 0.01).The levels of left ventricular ejection fraction(LVEF),fractional shortening of left ventricular short axis(FS),the ratio of maximum blood flow between the advanced and early atrial systole(E/A),stroke volume(SV),cardiac output(CO),and the cardiac index(CI) were all improved in both groups(P < 0.01 or P < 0.05),but better improvement were shown in the treated group.Followed-up study showed that the incidence of cardiac event were lower in the treated group than that in the control group(P < 0.05).Conclusions: AI can be took as one of the important auxiliary drugs treatment of CHF especially in severe case.